Grey Wolf Therapeutics (now referred to as Greywolf Therapeutics) was the second company established within the MTM ecosystem. Initially just an idea—seeded by Tom and Kirsty McCarthy—it became the first in the ecosystem to secure VC investment. 

Formed in September 2017, Grey Wolf was part of the MTM ecosystem for over seven and a half years, officially transitioning to a standalone entity on June 30, 2025. During this period, MTM supported the Company in raising more than £80M, successfully enabling the oncology molecule GRWD5769 entry into the clinic across Australia and Europe and advancing the autoimmune molecule GRWD0715 towards the clinic. Since then, under the direction of the Grey Wolf team, both molecules continue to progress and initial clinical data for GRWD5769 was presented at ASCO 2026 and GRWD0715 has commenced clinical trials.

Now operating with a fully independent team, Grey Wolf Therapeutics continues its important work. The MTM team is immensely proud to watch this alumni company, to which we dedicated years of effort, progress biotech assets from concept to clinic.

For more questions about Grey Wolf Therapeutics please visit their website.